Neuro-oNcology

Bevacizumab in combination with chemotherapy is now being studied for the treatment of malignant gliomas. However, the risk of intracranial hemorrhage has lim-ited its use in patients requiring full anticoagulation for venous thrombosis. To assess the safety of using antico-agulation with bevacizumab, we conducted a retrospec-tive review of our patients who were treated with beva-cizumab while receiving anticoagulation. We reviewed their medical records and imaging for signs of hemor-rhage. In total, we had 21 patients who received antico-agulation and bevacizumab concurrently for a median time of 72 days. Eighteen patients had adequate antico-agulation for venous thrombosis. There were no frank lobar hemorrhages in any patient. Three patients had small, intraparenchymal hemorrhages on MRI, but onl